<scp>TMB</scp>‐High, <scp>MSI</scp>‐High Castration‐Resistant Prostate Cancer Treated With Pembrolizumab
Genomic tests should be considered for high-grade tumors. MSI-high and TMB-high prostate cancer responded well to pembrolizumab in this case, but patients should be carefully monitored for the development of side effects after administration of pembrolizumab.
Authors
- Satoshi Muraoka
- Hiroki Kawabata
- Takahito Wakamiya (ORCID: https://orcid.org/0000-0001-9101-1749)
- Isao Hara (ORCID: https://orcid.org/0000-0003-4542-4045)
- Yasuo Kohjimoto (ORCID: https://orcid.org/0000-0001-6103-6320)
- Shimpei Yamashita (ORCID: https://orcid.org/0000-0001-7402-6164)
- Yuya Iwahashi (ORCID: https://orcid.org/0000-0002-4201-1985)
- Ryusuke Deguchi (ORCID: https://orcid.org/0000-0001-9573-8371)
- أحمد عبدالمجيد الصمادي
Institutions
- Wakayama Medical University (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1002/iju5.70062
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Wakayama Medical University